Aligos Therapeutics, Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Aardvark Therapeutics’ drug candidates are designed to reduce hunger, but the company worked up enough of an appetite among investors to support the company’s initial public offering – the fifth bioph

Aligos Therapeutics, Inc. may be able to improve on the safety and efficacy for the first drug approved for non-alcoholic/metabolic dysfunction-associated steatohepatitis (NASH/MASH), Madrigal Pharm

Lexeo Therapeutics Inc. became the 20th biopharma to launch an initial public offering in the US on 2 November when it sold 9.09 million shares at $11 each to gross $100m in its late-night public mar